Asthma is a respiratory condition,
where the airways become inflamed and narrow, which can cause a serious and incurable
condition if left untreated. Breathlessness, wheezing and coughing are some of
the symptoms of asthma and it can be controlled by avoiding triggers and with
the help of drug therapy. Environmental triggers may vary from consumer to
consumer but it can include exercise, smoke, cold air and other allergens such
as pollen, dust mites, and infections. The wheezing in asthma begins when the
chemicals present in the lungs overreact to the dust mites, cold air and exercise.
For
more information visit:
https://www.psmarketresearch.com/market-analysis/asthma-market
According to Centers for
Disease Control and Prevention (CDC), asthma is an ordinary chronic airway
disorder which is characterized by swelling of air passages that convey air
from mouth and nose to lungs. Asthma is caused generally due to allergies leading
to inflammation of lungs. GlaxoSmithKline Pharmaceuticals Limited and Novartis AG
are developing once-a-day combination products that are longer acting than
currently available drugs and more suitable for patients due to its advantage of
being taken only once a day.
The asthma drugs medications
can be categorized as relievers, such as beta-2 agonists-soothe, and controllers,
such as corticosteroids. On the basis of the treatment type, asthma market can be categorized as bronchodilators,
combination therapies and anti-inflammatories. Bronchodilators can further be
sub-categorized as short acting bronchodilators, anticholinergic,
bronchodilators and long acting bronchodilators. Anti-inflammatories can
further be sub-categorized as anti-leukotrienes, inhaled corticosteroids and monoclonal
antibodies.
